Company · Blainville, Quebec, Canada
Laboratoire Riva Inc.
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 520
- 283 authorized now
- Natural health products
- 38
- 26 active licences
- Medical device licences
- 0
- 0 active
- Notices of Compliance
- 464
Drug products
Authorized products first.
Showing 300 of 520 drug products. For the rest, search Health Canada’s database.
Natural health products
Active licences first, newest first.
| Name | NPN | Status | Licensed |
|---|---|---|---|
| RIVA-D 400 IU Drops | 80151098 | Active | |
| Vitamin B12 250 mcg | 80121070 | Active | |
| Vitamin B12 1000 mcg | 80121069 | Active | |
| RIVA-D 1000 Gelcaps | 80106651 | Active | |
| RIVA-D 400 Gel | 80105615 | Active | |
| RIVA-VITAMINE B12 | 80091214 | Active | |
| RIVA-CAL D1000 | 80073502 | Active | |
| RIVA-CAL D1000 | 80072757 | Active | |
| Riva-Cal D400 | 80065914 | Active | |
| Vitamine B12 100 mcg | 80055733 | Active | |
| IVY RELIEF | 80054267 | Active | |
| IVY RELIEF | 80054265 | Active | |
| RECTOGEL | 80034868 | Active | |
| VITA 3B | 80029701 | Active | |
| PSEUDOFRIN | 80028524 | Active | |
| VITA 3B +C | 80028252 | Active | |
| Calcite 500 + D 1000 | 80025501 | Active | |
| Viplex | 80021240 | Active | |
| Calcite 500 + D 800 | 80015972 | Active | |
| Riva-K 8 SR | 02244068 | Active | |
| Riva-K 20 SR | 02243975 | Active | |
| Calcium citrate + Vitamine D 400 UI | 80007293 | Active | |
| RIVA-D 400 I.U. | 80005560 | Active | |
| Calcite D 500 | 80004966 | Active | |
| Calcite 500 D 400 | 80004963 | Active | |
| Calcium 600 + D 400 | 80000441 | Active | |
| Riva-Senna 8.6 mg | 80079605 | Discontinued | |
| Calcite Liquide | 80064257 | Discontinued | |
| Calcite Liquide + D 400 | 80061575 | Discontinued | |
| Calcite Liquide + D 1000 | 80061569 | Discontinued | |
| Calcium 600 | 80061565 | Discontinued | |
| Riva-D 1000 | 80051562 | Discontinued | |
| Calcium 600 + D200 | 80050297 | Discontinued | |
| Calcium 600 + D400 | 80050299 | Discontinued | |
| RIVA-B12 1200 mcg XR | 80045810 | Discontinued | |
| RIVA-B12 1200 mcg XR | 80042365 | Discontinued | |
| RIVA SENNA | 01949292 | Discontinued | |
| Calcium 600 + D 200 | 80000287 | Discontinued |
Notices of Compliance
Newest first.
- RIVA SITAGLIPTINOctober 9, 2026 · NOC 38441 · Abbreviated New Drug Submission (ANDS)
- DOXYCIN CAPSULES; DOXYCIN TABLETSOctober 9, 2026 · NOC 38442 · Supplement to a New Drug Submission (SNDS)
- RIVA-ROSUVASTATINSeptember 29, 2026 · NOC 38387 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ISAVUCONAZOLESeptember 18, 2026 · NOC 38307 · New Drug Submission (NDS)
- DULOXETINESeptember 18, 2026 · NOC 38321 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-METFORMINSeptember 8, 2026 · NOC 38245 · Abbreviated New Drug Submission (ANDS)
- RAMIPRILAugust 31, 2026 · NOC 38211 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ISMNAugust 10, 2026 · NOC 38069 · Abbreviated New Drug Submission (ANDS)
- RIVA-CITALOPRAMAugust 5, 2026 · NOC 38059 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ZOPICLONEJuly 31, 2026 · NOC 38025 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-METFORMINJuly 22, 2026 · NOC 37964 · New Drug Submission (NDS)
- RIVA-ABIRATERONEJuly 15, 2026 · NOC 37916 · Abbreviated New Drug Submission (ANDS)
- RIVA-ATORVASTATINJuly 10, 2026 · NOC 37882 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA RIVAROXABANJune 30, 2026 · NOC 37810 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ATORVASTATINJune 2, 2026 · NOC 37645 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-CELECOXMay 20, 2026 · NOC 37578 · Supplement to an Abbreviated New Drug Submission (SANDS)
- DULOXETINEMay 15, 2026 · NOC 37554 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-DICLOFENACApril 28, 2026 · NOC 37410 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-DICLOFENACApril 28, 2026 · NOC 37413 · Abbreviated New Drug Submission (ANDS)
- RIVA-HYDROXYUREAApril 24, 2026 · NOC 37403 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVASA 81 MG ECApril 1, 2026 · NOC 37237 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-CINACALCETMarch 30, 2026 · NOC 37225 · Abbreviated New Drug Submission (ANDS)
- RIVA-CARVEDILOLMarch 26, 2026 · NOC 37192 · Abbreviated New Drug Submission (ANDS)
- RIVA-SIMVASTATINMarch 20, 2026 · NOC 37146 · Abbreviated New Drug Submission (ANDS)
- RIVA-CANDESARTANMarch 6, 2026 · NOC 37055 · Abbreviated New Drug Submission (ANDS)
- RIVA-DAPAGLIFLOZINFebruary 27, 2026 · NOC 37154 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA APIXABANFebruary 26, 2026 · NOC 36999 · Abbreviated New Drug Submission (ANDS)
- RIVA-PRAVASTATINFebruary 5, 2026 · NOC 36838 · Abbreviated New Drug Submission (ANDS)
- RIVA-LACOSAMIDEJanuary 27, 2026 · NOC 36791 · Abbreviated New Drug Submission (ANDS)
- RIVA-GABAPENTINJanuary 22, 2026 · NOC 36771 · Abbreviated New Drug Submission (ANDS)
- RIVA-MONTELUKAST; RIVA-MONTELUKAST FCJanuary 21, 2026 · NOC 36757 · Abbreviated New Drug Submission (ANDS)
- RIVA-DAPAGLIFLOZINJanuary 15, 2026 · NOC 36735 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ANASTROZOLEDecember 29, 2025 · NOC 36647 · Abbreviated New Drug Submission (ANDS)
- RIVA APIXABANDecember 23, 2025 · NOC 36612 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-AMLODIPINEDecember 17, 2025 · NOC 36567 · Abbreviated New Drug Submission (ANDS)
- DONEPEZILDecember 11, 2025 · NOC 36522 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ALENDRONATEDecember 9, 2025 · NOC 36502 · Abbreviated New Drug Submission (ANDS)
- RIVA-LATANOPROSTNovember 28, 2025 · NOC 36441 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ROSUVASTATINNovember 25, 2025 · NOC 36422 · Abbreviated New Drug Submission (ANDS)
- RIVA-FAMOTIDINEOctober 24, 2025 · NOC 36242 · Abbreviated New Drug Submission (ANDS)
- RIVA-RUPATADINEAugust 8, 2025 · NOC 35805 · Abbreviated New Drug Submission (ANDS)
- RIVA-HYDROXYUREAAugust 1, 2025 · NOC 35951 · Supplement to an Abbreviated New Drug Submission (SANDS)
- EZETIMIBEJuly 31, 2025 · NOC 35782 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-TELMISARTAN/AMLODIPINEJuly 31, 2025 · NOC 35783 · Abbreviated New Drug Submission (ANDS)
- RIVA-FLUOXETINEJuly 28, 2025 · NOC 35752 · Supplement to an Abbreviated New Drug Submission (SANDS)
- DIARRHEA RELIEF LIQUID GELSJuly 24, 2025 · NOC 35726 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ZOPICLONEJuly 7, 2025 · NOC 35624 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-CLINDAMYCINMay 30, 2025 · NOC 35448 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ESOMEPRAZOLEMay 16, 2025 · NOC 35363 · Abbreviated New Drug Submission (ANDS)
- DULOXETINEApril 8, 2025 · NOC 35142 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA RIVAROXABANMarch 21, 2025 · NOC 35045 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-DORZOLAMIDE/TIMOLOLMarch 12, 2025 · NOC 35000 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ROSUVASTATINFebruary 24, 2025 · NOC 34893 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-SILDENAFILJanuary 3, 2025 · NOC 34634 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-FINASTERIDEDecember 27, 2024 · NOC 34630 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-PREGABALINDecember 6, 2024 · NOC 34517 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-AMIODARONENovember 7, 2024 · NOC 34337 · Abbreviated New Drug Submission (ANDS)
- RIVA-OXYBUTYNINOctober 29, 2024 · NOC 34295 · Supplement to a New Drug Submission (SNDS)
- RIVA-BACLOFENOctober 18, 2024 · NOC 34231 · Supplement to a New Drug Submission (SNDS)
- DIARRHEA RELIEF LIQUID GELSOctober 11, 2024 · NOC 34218 · Abbreviated New Drug Submission (ANDS)
- RIVA-GABAPENTINSeptember 9, 2024 · NOC 33981 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-IRBESARTANSeptember 3, 2024 · NOC 33918 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ESCITALOPRAMAugust 27, 2024 · NOC 33873 · Supplement to an Abbreviated New Drug Submission (SANDS)
- VENLAFAXINE XRAugust 13, 2024 · NOC 33811 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TOBRAMYCIN INHALATION SOLUTION USPAugust 8, 2024 · NOC 33776 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-OMEPRAZOLE DRJuly 31, 2024 · NOC 33731 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ZOPICLONEJuly 9, 2024 · NOC 33594 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA ALENDRONATE; RIVA-ALENDRONATE FCJuly 4, 2024 · NOC 33576 · Abbreviated New Drug Submission (ANDS)
- RIVA-LETROZOLEJuly 3, 2024 · NOC 33560 · Abbreviated New Drug Submission (ANDS)
- RIVA-FINASTERIDEJune 28, 2024 · NOC 33529 · Abbreviated New Drug Submission (ANDS)
- RIVA-FINASTERIDEJune 28, 2024 · NOC 33530 · Abbreviated New Drug Submission (ANDS)
- RIVA-SERTRALINEJune 28, 2024 · NOC 33532 · Abbreviated New Drug Submission (ANDS)
- DIARRHEA RELIEFJune 26, 2024 · NOC 33520 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-LOPERAMIDEJune 19, 2024 · NOC 33487 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-AZITHROMYCINJune 18, 2024 · NOC 33468 · Abbreviated New Drug Submission (ANDS)
- EZETIMIBEJune 11, 2024 · NOC 33431 · Abbreviated New Drug Submission (ANDS)
- RIVA APIXABANJune 4, 2024 · NOC 33387 · Abbreviated New Drug Submission (ANDS)
- RIVA-ALENDRONATEApril 26, 2024 · NOC 33131 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-CITALOPRAMMarch 28, 2024 · NOC 32973 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-SITAGLIPTIN TARTRATE/METFORMINFebruary 28, 2024 · NOC 32807 · Abbreviated New Drug Submission (ANDS)
- RIVA SITAGLIPTIN/METFORMINFebruary 27, 2024 · NOC 32781 · Abbreviated New Drug Submission (ANDS)
- SITAGLIPTINFebruary 21, 2024 · NOC 32750 · Abbreviated New Drug Submission (ANDS)
- RIVA-ATENOLOLFebruary 13, 2024 · NOC 32685 · Supplement to a New Drug Submission (SNDS)
- RIVA-RISPERIDONEFebruary 13, 2024 · NOC 32687 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-FLUCONAZOLEFebruary 9, 2024 · NOC 32683 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ATORVASTATINFebruary 8, 2024 · NOC 32667 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ANASTROZOLEJanuary 25, 2024 · NOC 33531 · Abbreviated New Drug Submission (ANDS)
- RIVA-SERTRALINEJanuary 4, 2024 · NOC 32460 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-LANSOPRAZOLEDecember 20, 2023 · NOC 32391 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RAMIPRILDecember 18, 2023 · NOC 32372 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PANTOPRAZOLEDecember 15, 2023 · NOC 32348 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-PANTOPRAZOLEDecember 6, 2023 · NOC 32297 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-ROSUVASTATINDecember 6, 2023 · NOC 32304 · Supplement to an Abbreviated New Drug Submission (SANDS)
- VENLAFAXINE XRNovember 16, 2023 · NOC 32118 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-AMLODIPINENovember 10, 2023 · NOC 32074 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-DUTASTERIDENovember 8, 2023 · NOC 32049 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA RIVAROXABANNovember 1, 2023 · NOC 31983 · Abbreviated New Drug Submission (ANDS)
- RIVA-LEVETIRACETAMOctober 27, 2023 · NOC 31951 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-LATANOPROSTOctober 25, 2023 · NOC 31945 · Supplement to an Abbreviated New Drug Submission (SANDS)
- RIVA-CIPROFLOXACINOctober 20, 2023 · NOC 31912 · Supplement to an Abbreviated New Drug Submission (SANDS)
The latest 100 of 464.
Recalls and safety alerts that mention its products
Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.
- RIVA-Fluoxetine 10 mg capsule; may exceed the interim acceptable intake limit for N-nitroso-fluoxetineJuly 3, 2025 · Drugs · Product quality · Type I
- Rivasa 81 mg EC tablet; Out of specification (salicylic acid impurity)June 6, 2025 · Drugs · Product quality · Type III
- RIVA-FLUOXETINE: Affected lots exceed the interim acceptable intake limit for N-nitroso-fluoxetine.April 29, 2025 · Drugs · Product quality · Type I
- Riva-Oxazepam: Incorrect label (Riva-Oxazepam 30MG 500 tablets DIN00568414) may be appended to affected lots that contains: Riva-Oxazepam 15MG 500 tablets DIN00568406September 22, 2022 · Drugs · Labelling · Type II
- Recall: One lot of Riva-Risperidone 0.25 mg tablets recalled due to a packaging errorOctober 9, 2021 · Drugs
- Riva-Risperidone (2021-10-07)October 7, 2021 · Drugs · Product safety · Type I
- Riva-Senna 8.6 mg(2021-03-03)March 3, 2021 · Natural health products · Product safety · Type II
- Riva-Escitalopram (2017-08-14)September 26, 2017 · Drugs · Product safety · Type III
- Riva-CitalopramJanuary 30, 2017 · Drugs · Product safety · Type II
- RIVA-Olanzapine (2015-02-18)February 26, 2015 · Drugs · Product safety · Type II
- Riva-Pantoprazole (2014-04-03)April 8, 2014 · Drugs · Product safety · Type III
- Riva-Ciprofloxacin - 500 mgJune 6, 2013 · Drugs · Product quality - Product safety · Type II
- Riva-Quetiapine 25 mgJune 4, 2013 · Drugs · Contamination - Product safety · Type I
- Riva-Quetiapine 300 mgJune 4, 2013 · Drugs · Contamination - Product safety · Type I
- Riva-Quetiapine 100 mgJune 4, 2013 · Drugs · Contamination - Product safety · Type I
- Riva-Quetiapine 200 mgJune 3, 2013 · Drugs · Contamination - Product safety · Type I
- Riva-Quetiapine (quetiapine fumarate) - Voluntary Recall Due to Possible Contamination Issues - For Health ProfessionalsMay 21, 2013 · Drugs · Contamination
- Riva-PravastatinApril 23, 2013 · Drugs · Product safety · Type II
- Riva-Simvastatin - 10 mg and 20 mgFebruary 18, 2013 · Drugs · Product safety · Type II
- Riva-SimvastatinFebruary 20, 2012 · Drugs · Type II
- Riva-SimvastatinFebruary 20, 2012 · Drugs · Type II
- Riva-SimvastatinFebruary 20, 2012 · Drugs · Type II